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A b s t r a c t
Background: Although lactate is a well-established marker in intensive care, our understanding of its utility in acute heart 
failure (AHF) is modest and based on studies with a single measurement of this marker.
Aim: We aimed to investigate whether persistent elevation of lactate during hospitalisation is related to a higher risk of ad-
verse events.
Methods: We conducted a prospective study to assess AHF patients hospitalised in one cardiac centre. The diagnosis of 
persistent hyperlactataemia was based on two measurements of the marker (on admission and at 24 h of hospitalisation) and 
it was defined as lactate elevation (≥ 2 mmol/L) at both time points.
Results: The population consisted of 222 patients at a mean age of 70 ± 13 years. Mean ejection fraction and creatinine level 
on admission were 37% ± 16% and 1.36 ± 0.51 mg/dL, respectively. The percentage of patients with elevated lactates on 
admission, at 24 h of hospitalisation, and persistent hyperlactataemia were 47%, 35%, and 24%, respectively. The group with 
persistent hyperlactataemia did not differ in most clinical and laboratory variables from the rest of the population. Patients 
with persistent hyperlactataemia had higher rate of adverse events during hospitalisation: worsening of heart failure (22.6% 
vs. 6.5%, p < 0.05), inotrope use (22.6% vs. 5.3%, p < 0.05), and increase of N-terminal pro–B-type natriuretic peptide 
at 48 h of hospitalisation (30% vs. 18%, p < 0.05). Persistent hyperlactataemia was an independent predictor of one-year 
mortality (hazard ratio 2.5, 95% confidence interval 1.5–4.3, p < 0.001).
Conclusions: Persistent hyperlactataemia within the first 24 h of hospitalisation is a predictor of a worse outcome in AHF and 
is related to higher rates of in-hospital adverse events and one-year mortality.
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INTRODUCTION
Lactate is an end-product of the anaerobic pathway of energy 
production [1–3]. In humans, the anaerobic metabolism is 
mainly used to maintain the production of energy despite the 
lack of adequate oxygen supply [2]. This process is inefficient, 
but it is critical to survive stress conditions and to adapt to 
this transient, unfavourable situation [4]. Under normal steady 
conditions, lactate is continuously produced (at low levels) and 
cleared to maintain its low concentration [3]. Thus, lactate 
is a metabolic marker widely used in many different clinical 
scenarios, mainly in intensive care medicine [2, 5–10]. The 
physiological information it carries is also used in endurance 
sports because intense exercise leads to lactate accumulation 
even in the absence of any overt pathology [11]. Unlike other 
widely used markers in heart failure (HF), lactate is unique 
because it reflects the dynamic energetic/metabolic status of 
the patient [12–16]. It does not reflect the severity of heart 
dysfunction itself, but rather the metabolic consequences of 
the insult driven by the decompensation and its severity in 
each patient.
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However, the data on lactate utility in HF remain limited 
[4, 17–20]. Only recently, we showed that a single lactate 
measurement on admission in acute HF (AHF) patients with-
out overt clinical signs of hypoperfusion may help identify 
individuals with end-organ dysfunction and worse prognosis 
[19]. It remains unknown whether AHF patients who are 
able to clear lactate accumulated on admission during the 
first hours of hospitalisation have different clinical course 
and prognosis than those with persistent hyperlactataemia.
Therefore, we aimed to extend our knowledge and 
investigate whether dynamic changes in lactate levels during 




This was a single-centre, prospective, observational study. 
The study population consisted of patients admitted to the 
Centre of Heart Diseases, Fourth Military Hospital, Wroclaw, 
Poland, enrolled between 2016 and 2017. Inclusion criteria 
comprised AHF as the primary cause of hospitalisation (AHF 
was diagnosed according to guideline criteria of the European 
Society of Cardiology [ESC]) and written consent of the patient 
to participate in the study [21]. Exclusion criteria included 
cardiogenic shock, the need for intra-aortic balloon pump 
implantation, clinical diagnosis of concurrent acute coronary 
syndrome or infection, and known severe liver disease or renal 
disease requiring or with planned renal replacement therapy. 
After inclusion, information on demographics, clinical history, 
comorbidities, previous therapies, and physical examination 
findings was recorded. Clinical and laboratory assessments 
including (but not limited to) an evaluation of the clinical sings 
of HF, as well as assessment of dyspnoea and HF worsening, 
were performed by attending clinicians on admission, at 24 h, 
at 48 h, and at discharge. 
According to the protocol, lactate levels were measured 
on admission and at 24 h of hospitalisation as part of standard 
blood testing to assess capillary blood oxygen saturation and 
acid-base balance. 
Patients were treated in accordance with the recommen-
dations of the attending physicians, which are in line with the 
ESC guidelines [21], rather than by protocol. The research was 
approved by the local Ethics Committee, and all participants 
gave written, informed consent. The study was conducted in 
compliance with the Declaration of Helsinki.
Laboratory measurements
At the predefined time points, the following laboratory meas-
urements were recorded using standard methods: 
 — capillary blood for oxygen saturation, carbon dioxide 
concentration, pH, bicarbonate, and lactate (direct 
method, ABL 800 Flex analyser, Radiometer, Copenha-
gen, Denmark) (on admission and at 24 h);
 — haematology: haemoglobin, white blood cell count, and 
platelet count (on admission and at 48 h);
 — serum electrolytes: sodium (Na+) and potassium (K+) (on 
admission, at 24 h, and at 48 h);
 — renal function tests: creatinine and blood urea nitrogen 
(on admission, at 24 h, and at 48 h);
 — liver function tests: aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), bilirubin, and albumin 
(on admission);
 — plasma N-terminal pro–B-type natriuretic peptide 
(NT-proBNP; immunoenzymatic assay, Siemens, Mar-
burg, Germany) (on admission and at 48 h).
Definitions
On the basis of previous reports, for the purposes of this 
analysis, elevated lactate was defined as lactate ≥ 2 mmol/L 
[19, 21]. Persistent hyperlactataemia was defined as elevated 
lactate at both timepoints: on admission and at 24 h of 
hospitalisation. Patients in whom elevation of lactate was 
found only at one time point did not fulfil the definition 
of persistent hyperlactataemia and were classified to the 
non-persistent hyperlactataemia group. Persistent tachycardia 
was defined as heart rate > 100 bpm on admission and at 
24 h, persistent hypotension was defined as systolic blood 
pressure (SBP) < 100 mmHg on admission and at 24 h, and 
persistent pulmonary congestion was defined as the pres-
ence of any congestion on admission and at 24 h assessed 
by auscultation. 
Clinical follow-up
Surviving patients were followed in the Heart Failure Clinic 
for at least 365 days. Information was either obtained directly 
from patients or their relatives (telephone contact) or from the 
Heart Failure Clinic, the hospital system database, or the central 
authority census. No patient was lost to follow-up. All-cause 
mortality at one year was the primary endpoint of interest.
Statistical analysis 
Continuous variables with normal distribution were described 
using means ± standard deviation, variables with skewed 
distribution were described by medians with upper and lower 
quartiles, and categorical variables were given as numbers and 
percentages. The statistical significance of differences between 
the groups was assessed using: Student t test, Mann-Whitney 
U-test, or c2 test where appropriate. The Cox proportional 
hazards model was used to calculate the hazard ratio (HR) with 
corresponding 95% confidence interval (CI) for all-cause mor-
tality. The multivariate analyses were adjusted for age, serum 
creatinine, serum Na+, SBP, and NT-proBNP. Kaplan-Meier 
survival curves were constructed to demonstrate the survival. 
A p-value < 0.05 was considered statistically significant. 
Statistical analyses were performed using the STATISTICA 
13 software (StatSoft Poland, Krakow, Poland). 
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The study population consisted of 222 patients (164 [74%] 
men) at a mean age of 70 ± 13 years. A total of 88 (39%) 
patients had de novo AHF. The median (25th–75th quartiles) 
plasma levels of NT-proBNP and troponin I were 5654 pg/mL 
(3365–12081 pg/mL) and 0.06 pg/mL (0.03–0.17 ng/mL), 
respectively. Mean lactate levels on admission and at 24 h of 
hospitalisation were 2.2 ± 1.2 mmol/L and 2.1 ± 1.2 mmol/L, 
respectively. The detailed baseline characteristics of the pa-
tients are shown in Table 1.
Percentage of patients with elevated  
lactate during hospitalisation 
There were 47% of patients with lactate levels ≥ 2 mmol/L 
on admission. During the first 24 h of hospitalisation, the 
percentage of patients with lactate levels above the cut-off 
value dropped to 35% (Fig. 1). There were 53 (24%) patients 
with persistent hyperlactataemia (Fig. 1).
Comparison of patients with and without  
persistent hyperlactataemia 
There were no differences between patients with and without 
persistent hyperlactataemia in terms of SBP (127 ± 32 mmHg 
vs. 136 ± 31 mmHg, p > 0.05), creatinine (1.3 ± 0.5 mg/dL 
vs. 1.4 ± 0.5 mg/dL, p > 0.05), and serum Na+ (138 ± 5 mmol/L 
vs. 139 ± 4 mmol/L, p > 0.05) on admission. However, pa-
tients with persistent hyperlactataemia had higher heart rate 
(102 ± 27 bpm vs. 86 ± 21 bpm, p < 0.05), haemoglobin 
(13.9 ± 1.9 g/dL vs. 13.1 ± 1.9 g/dL, p < 0.05), and biliru-
bin (1.99 ± 2.1 mg/dL vs. 1.26 ± 1.0 mg/dL, p < 0.05) on 
admission. The group with persistent hyperlactataemia had 
significantly higher lactate levels at both time points (Table 2). 
There was no difference in the percentage of patients with 
in-hospital treatment as well as clinical manifestations of HF 
(oedema, pulmonary congestion, ascites, elevated jugular 
venous pressure, or hepatomegaly) between the two groups 
on admission (Table 2).




Male sex 164 (74)
Age [years] 70 ± 13
Heart rate [bpm] 90 ± 24
SBP on admission [mmHg] 134 ± 31
DBP on admission [mmHg] 79 ± 16
LVEF [%] 37 ± 16
Acute HF (de novo) 88 (39)
Ischaemic aetiology of HF 115 (52)
Blood count:
Haemoglobin [g/dL] 13.3 ± 1.9
WBC [g/L] 9.2 ± 4.5
Platelets [g/L] 209 ± 88
AST [IU/L] 28 [21–40]
ALT [IU/L] 31 [22–56]
Bilirubin [mg/dL] 1.02 [0.72–1.71]
Serum sodium [mmol/L] 139 ± 4
Creatinine [mg/dL] 1.36 ± 0.51
BUN [mg/dL] 28 ± 14.4
CRP [mg/L] 7.7 [4.2–18]
NT-proBNP [pg/mL] 5654 [3365–12081]
Troponin I [ng/mL] 0.06 [0.03–0.17]
SBP at 24 h [mmHg] 122 ± 23
Creatinine at 24 h [mg/dL] 1.3 ± 0.5
Length of hospitalisation [days] 8 ± 6
Lactate on admission [mmol/L] 2.2 ± 1.2 
2.0 [1.5–2.6]
Lactate at 24 h [mmol/L] 2.1 ± 1.2 
1.8 [1.5–2.4]
Data shown as number (percentage), mean ± standard deviation or 
median [25th–75th quartiles]. ALT — alanine aminotransferase; AST —  
aspartate aminotransferase; BUN — blood urea nitrogen, CRP — 
C-reactive protein; DBP — diastolic blood pressure; HF — heart failure; 
LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal  
pro–B-type natriuretic peptide; SBP — systolic blood pressure;  
WBC — white blood cell count
Conversion factor to SI units: for haemoglobin [g/dL] — 10 [g/L], for 
leukocytes [G/L] — 1, for platelets [G/L] — 1; for creatinine [mg/dL] — 
88.4 [µmol/L]; for CRP — 9.52 [nmol/L]; for plasma NT-proBNP levels 
[pg/mL] — 0.1182 [pmol/L] 
Figure 1. Percentage of patients (n = 222) with elevated 
lactate (≥ 2 mmol/L) 
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Table 2. Comparison of patients with and without persistent hyperlactataemia





Male sex 124 (73) 40 (75) 0.76
Age [years] 71 ± 13 66 ± 12 0.23
Heart rate [bpm] 86 ± 21 102 ± 27 < 0.0001
SBP on admission [mmHg] 136 ± 31 127 ± 32 0.10
DBP on admission [mmHg] 79 ± 16 77 ± 17 0.55
LVEF [%] 38 ± 14 34 ± 13 0.06
Acute HF (de novo) 94 (57) 36 (68) 0.15
Ischemic aetiology of HF 84 (50) 31 (58) 0.23
Blood count:
Haemoglobin [g/dL] 13.1 ± 1.9 13.9 ± 1.9 < 0.005
WBC [g/L] 8.6 ± 4.0 10.6 ± 5.3 0.004
Platelets [G/L] 203 ± 87 216 ± 86 0.35
AST [IU/L] 27 [20–38] 33 [25–70] 0.004
ALT [IU/L] 30 [21–53] 33 [25–109] 0.02
Bilirubin [mg/dL] 1.26 ± 1.0 1.99 ± 2.1 0.001
Serum sodium [mmol/L] 139 ± 4 138 ± 5 0.09
Creatinine [mg/dL] 1.4 ± 0.5 1.3 ± 0.5 0.68
BUN [mg/dL] 25 [18–35] 24 [18–32] 0.78
CRP [mg/L] 7 [3–17] 10 [6-29] 0.02
NT-proBNP [pg/mL] 5581 [3476–12118] 5664 [3129–12081] 0.92
Troponin I [ng/mL] 0.05 [0.03–0.11] 0.09 [0.04–0.62] 0.007
SBP at 24 h [mmHg] 123 ± 31 113 ± 22 < 0.005
Creatinine at 24 h [mg/dL] 1.3 ± 0.5 1.2 ± 0.4 0.12
Length of hospitalisation [days] 8 ± 5 10 ± 7 0.02
Lactate on admission [mmol/L] 1.9 ± 0.8  
1.7 [1.3–2.1]
3.3 ± 1.5  
2.8 [2.3–3.4]
< 0.0001
Lactate at 24 h [mmol/L] 1.7 ± 0.5  
1.7 [1.5–1.9]




Furosemide (yes) 169 (100) 53 (100) 1.0
Nitroglycerine (yes) 90 (53) 26 (49) 0.59
ACEI/ARB (yes) 139 (82) 47 (89) 0.25
b-blocker (yes) 164 (97) 50 (94) 0.35
MRA (yes) 66 (39) 16 (30) 0.24
Oedema on admission: 0.5
No 45 (27) 19 (36)
1+ 42 (25) 8 (15)
2+ 47 (28) 14 (26)
3+ 35 (21) 12 (23)
Pulmonary congestion on admission: 0.2
No 15 (9) 8 (15)
< 1/3 lungs 96 (57) 28 (53)
> 1/3 lungs 57 (34) 17 (32)
Ascites (yes) 23 (14) 5 (9) 0.4
JVP > 6 cm (yes) 52 (31) 16 (30) 0.2
Hepatomegaly (yes) 26 (15) 9 (17) 0.7
Data shown as number (percentage), mean ± standard deviation or median [25th–75th quartiles]. ACEI/ARB — angiotensin-converting enzyme 
inhibitors/angiotensin-receptor blockers; JVP — jugular venous pressure; MRA — mineralocorticoid receptor antagonist; other abbreviations  
— see Table 1
*Defined as elevated lactate (≥ 2 mmol/L) on admission and at 24 h of hospitalisation.
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In-hospital clinical course of patients with  
and without persistent hyperlactataemia
A higher percentage of patients from the group with persistent 
hyperlactataemia were initially admitted to the cardiac intensive 
care unit (CICU) (43% vs. 18%, p < 0.005) and needed to be 
readmitted to the CICU during hospitalisation (16.9% vs. 7.6%, 
p = 0.07). Moreover, a higher percentage of patients in this 
group had worsening of HF during hospitalisation (22.6% 
vs. 6.5%, p = 0.002), increased NT-proBNP level on the second 
day of hospitalisation (30% vs. 18%, p = 0.04), and needed 
inotropic support (22.6% vs. 5.3%, p = 0.001). In-hospital 
mortality (13.2% vs. 1.8%, p < 0.001) and the length of hospital 
stay (10 ± 7 days vs. 8 ± 5 days, p = 0.02) were also higher 
in the group of persistent hyperlactataemia (Tables 2 and 3).
Predictive value of serial lactate  
assessment in AHF 
There were 62 (28%) deaths during 365 days of follow-up, 
including 10 (4.5%) deaths during hospitalisation. Lactate 
level, which was assessed at two time points (on admission 
and at 24 h of hospitalisation), was a strong prognosticator of 
one-year mortality (HR 1.5, 95% CI 1.2–1.8, p < 0.01 and 
HR 1.5, 95% CI 1.2–1.8, p < 0.01, respectively). Moreo-
ver, after dichotomisation of lactate at a cut-off value of 
2 mmol/L, it remained significant at both time points (Table 4). 
Patients with persistent hyperlactataemia had significantly 
higher risk of death during the one-year follow up (HR 2.4, 
95% CI 1.4–3.4, p = 0.002). The risk was independent of 
other well-established prognosticators, such as age, serum 
creatinine, serum Na+, SBP, or NT-proBNP (HR 2.5, 95% CI 
1.5–4.3, p < 0.001) as well as of clinical markers of adverse 
clinical course, such as persistent tachycardia (defined as 
heart rate > 100 bpm on admission and at 24 h), persistent 
hypotension (defined as SBP < 100 mmHg on admission 
and at 24 h), persistent pulmonary congestion (on admission 
and at 24 h), and worsening of HF during hospitalisation 
(HR 2.0, 95% CI 1.2–3.4, p < 0.01). During the follow-up 
period, there were 24 (45%) deaths in the hyperlactataemia 
group vs. 38 (22%) deaths in the rest of the population; the 
Kaplan-Meier curves demonstrating the survival are shown in 
Figure 2A (p = 0.001). 
In order to clarify whether the difference in mortality risk 
between patients with and without persistent hyperlactataemia 
was not biased by patients without any elevation of lactate, we 
performed an additional analysis. The population was divided 
into three groups: patients with persistent hyperlactataemia 
(lactate ≥ 2 mmol/L at both timepoints; n = 53) vs. patients 
with lactate ≥ 2 mmol/L only at one time point (either on 
admission or at 24 h; n = 77) vs. patients without elevation 
of lactate (lactate < 2 mmol/L at both timepoints; n = 92). 
The percentage of patients who died during follow-up was: 
45.3% vs. 25% vs. 21%, respectively (p < 0.05). Kaplan-Meier 
curves demonstrating the survival in those groups are shown 
in Figure 2B (p = 0.004).
DISCUSSION
There are at least four major novel findings of our analyses. To 
the best of our knowledge, we have shown for the first time that 
persistent hyperlactataemia, which was defined as elevated 
lactate level (≥ 2 mmol/L) on admission and at 24 h of hospi-
talisation, is related to higher rates of in-hospital adverse events 
and higher one-year mortality in AHF patients. Our data sup-
port the hypothesis that AHF patients with insufficient lactate 
clearance have poor prognosis. It remains unknown whether 
persistent hyperlactataemia is caused by excessive lactate pro- 
duction or its low elimination, but most likely both factors 
contribute to this result. A simple, physiological explanation 
of our observation is that patients who are able to clear the 
lactate (during the first 24 h of treatment) should have better 
prognosis despite the initial lactate accumulation because they 
are able to restore the aerobic metabolism more efficiently [9]. 
Thus, the decrease of lactate may be an early marker of 
microcirculatory restoration and better global energy metabo-
lism [2, 8, 22]. Coherent results have already been reported 
Table 3. Comparison of in-hospital adverse events in patients with and without persistent hyperlactataemia
Variables c2 No persistent hyperlactataemia Persistent hyperlactataemia* p
Initial admission to CICU 14 30 (18) 23 (43) 0.0002
Need for readmission to CICU 3.1 13 (7.6) 9 (16.9) 0.07
Worsening of HF during hospitalisation** 9.7 11 (6.5) 12 (22.6) 0.002
Inotrope use during hospitalisation 10.9 9 (5.3) 12 (22.6) 0.001
In-hospital death 11.1 3 (1.8) 7 (13.2) 0.0008
Increase in NT-proBNP level at 48 h 4.2 31 (18) 16 (30) 0.04
JVP > 6 cm on day 2 3.5 18 (11) 11 (21) 0.07
Pulmonary congestion on day 2 1.7 48 (29) 20 (38) 0.19
Data are shown as number (percentage). CICU — cardiac intensive care unit; other abbreviations — see Tables 1 and 2
*Defined as lactate ≥ 2 mmol/L on admission and at 24 h of hospitalisation; **Assessed by attending cardiologist’s clinical judgment
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in critical care populations [9]. Although we provide the data 
on lactate assessed early during the hospitalisation (within the 
first 24 h), it would also be very interesting to examine its util-
ity as a maker measured at discharge. In this context we may 
only speculate that it might be a decision-making variable; 
however, this needs further prospective research. 
The pathophysiology of lactate accumulation in HF is 
complex [1, 4, 7]. Only recently, we have shown in a cohort 
of HF patients who had undergone haemodynamic monitoring 
that lactate was moderately correlated with central haemo-
dynamics (cardiac index) and that the strongest determinants 
of lactate included mixed venous oxygen saturation, systemic 
Table 4. Predictors of one-year mortality — univariate and multivariate analyses
Variables c2 HR (95% CI) p
Lactate on admission (per 1 mmol/L) 11.6 1.5 [1.2–1.8] 0.0002
Lactate at 24 h (per 1 mmol/L) 17.3 1.5 [1.2–1.8] < 0.0001
Lactate ≥ 2 mmol/L on admission 4.6 1.7 [1.0–2.9] 0.03
Lactate ≥ 2 mmol/L at 24 h 5.7 1.8 [1.1–3.1] 0.02
Persistent hyperlactataemia* 8.8 2.4 [1.4–3.9] 0.002
Baseline values on admission:
SBP (per 1 mmHg) 5.4 0.9 [0.9–0.9] 0.03
DBP (per 1 mmHg) 9.1 0.9 [0.9–.0.9] < 0.004
Heart rate (per 1 bpm) 1.8 0.9 [0.9–1.0] 0.2
Serum sodium (per 1 mmol/L) 10.8 0.9 [0.9–0.9] < 0.0005
BUN (per 1 mg/dL) 7.2 1.0 [1.0–1.0] 0.003
Creatinine (per 1 mg/dL) 7.6 1.8 [1.2–2.5] 0.002
Haemoglobin (per 1 g/dL) 1.1 0.9 [0.8–1.0] 0.2
NT-proBNP (log) [pg/mL] 11.7 1.0 [1.0–1.0] 0.0002
Multivariate analyses:
Persistent hyperlactataemia*# 37.7 2.5 [1.5–4.3] < 0.001
Persistent hyperlactataemia*## 20.9 2.0 [1.2–3.4] 0.007
*Defined as elevated lactate (≥ 2 mmol/L) on admission and at 24 h of hospitalisation; #Adjusted for age, serum creatinine, serum sodium, SBP, 
NT-proBNP; ##Adjusted for persistent tachycardia (defined as heart rate > 100 bpm on admission and at 24 h), persistent hypotension (defined 
as SBP < 100 mmHg on admission and at 24 h), persistent pulmonary congestion (on admission and at 24 h) and worsening of HF during hospi-
talisation. CI — confidence interval; HR — hazard ratio; other abbreviations — see Table 1
Figure 2. Kaplan-Meier curves; A. Comparison of patients with and without persistent hyperlactataemia; B. Comparison of patients 
with persistent hyperlactataemia vs. patients with lactate ≥ 2 mmol/L only at one time point vs. patients without hyperlactataemia
A B
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vascular resistance, and heart rate [18]. Indeed, the present 
analysis seems to confirm our previous observation because 
significantly higher heart rate on admission was reported for 
the group with persistent hyperlactataemia. The question of 
whether hyperlactataemia is a result of more extensive insult 
(decompensation) or reduced compensatory capabilities of 
AHF patients remains unanswered. Furthermore, the group 
with persistent hyperlactataemia showed signs of liver dysfunc-
tion (higher AST, ALT, and bilirubin), which may lead to limited 
clearance abilities of the organism. On the other hand, the 
observed liver injury may be a result of higher metabolic stress 
driven by the decompensation itself. Interestingly, the group 
with persistent hyperlactataemia had significantly higher levels 
of haemoglobin when compared to the rest of the population. 
This phenomenon has already been noted in our previous 
paper and is difficult to explain. We may only conclude that 
the hyperlactataemia is definitely not a maker of hypoxia that 
is driven by “simple” anaemia [18]. Thus, this observation 
supports the hypothesis that the pathophysiology of lactate 
accumulation is beyond simple tissue hypoxia. 
Secondly, there were no obvious signs indicating worse 
clinical course in the group of persistent hyperlactataemia on 
admission because there were no differences in most clinical 
signs of HF and laboratory variables on admission (e.g. SBP, 
Na+, renal function, and NT-proBNP) [16, 23]. However, it 
should be stressed that higher heart rate and worse liver func-
tion on admission, which are known prognosticators in HF, 
were observed in the hyperlactataemia group [12, 24–27]. But 
most importantly, patients who were not able to clear lactate 
within 24 h were more likely to experience in-hospital adverse 
events, such as worsening of HF, need for inotropes, increased 
NT-proBNP level at 48 h, and in-hospital death. To explain this 
observation, we may only speculate that the hyperlactataemia 
group included patients with ongoing, clinically undetected 
energetic debt that led to in-hospital complications and poor 
outcome. Moreover, this also shows that lactate is a unique 
HF marker because it reflects the dynamic metabolic status of 
the patient rather than the static degree of myocardial damage 
or dysfunction (such as NT-proBNP, troponin I). For the first 
time, we have linked the metabolic/energetic status of AHF 
patients during hospitalisation with adverse clinical scenarios. 
Thirdly, we have shown that lactate measured during 
hospitalisation has prognostic importance. Previous papers 
have shown clinical utility of a single (admission) lactate 
measurement in AHF populations [17, 19, 20]. Thus, we 
have demonstrated that serial assessment of lactate during 
hospitalisation may help to identify patients with higher 
one-year mortality. The multivariate analyses confirmed that 
persistent hyperlactataemia was an independent prognostica-
tor of one-year mortality. The persistent elevation of lactate 
remained an independent prognosticator after adjustment 
for other factors associated with unfavourable clinical course, 
such as persistent hypotension, tachycardia, and conges-
tion (present on admission and at 24 h of hospitalisation). 
Moreover, there was no difference in prognostic significance 
between lactate measured on admission and at 24 h of hospi-
talisation (data not shown). Interestingly, the visual analysis of 
Kaplan-Meier curves revealed that the group with persistent 
hyperlactataemia were at risk of significantly higher mortality 
mainly during the first 60 days of follow-up.
The additional analyses (Fig. 2B) revealed that the differ-
ence between the groups with vs. without persistent hyper-
lactataemia was not biased by a relatively low risk related to 
patients without any elevation of lactate levels. Moreover, the 
curves rather suggest that the mortality risk assessed only at 
a single time point may actually be influenced by the patients 
who have persistent hyperlactataemia in both time points.
Fourthly, there were a significant number of patients 
with elevated lactate during hospitalisation because ap-
proximately one-third of the study population still had lactate 
levels ≥ 2 mmol/L after 24 h of treatment. Although a de-
crease in lactate levels was observed during the first day of 
treatment, much lower levels would be expected. Moreover, 
almost one-fourth of patients had persistent hyperlactataemia, 
which indicated an ongoing energy deficit that is usually not 
identified based on a simple clinical assessment.
The arbitrary cut-off value used for the analyses 
(2 mmol/L) is based on previous reports and our understand-
ing of lactate physiology [19, 21]. However, we need to stress 
that each patient population (e.g. patients with sepsis, car-
diogenic shock, previous cardiac arrest, etc.) as well as each 
individual patient may have their own lactate cut-off value for 
prognosis. Thus, it is likely that higher values of lactate may 
overperform the value we used in HF patients.
We can conclude that persistent hyperlactataemia within 
the first 24 h of hospitalisation for AHF is an ominous sign 
and is related to higher rates of adverse events and higher 
one-year mortality.
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